cbdMD, Inc. Files Amendment to August 15th Report
Ticker: YCBD · Form: 8-K/A · Filed: Aug 19, 2024 · CIK: 1644903
| Field | Detail |
|---|---|
| Company | Cbdmd, Inc. (YCBD) |
| Form Type | 8-K/A |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $230,000, $255,000, $550,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, regulatory-filing
TL;DR
cbdMD filed an amendment to an earlier report, no new info yet.
AI Summary
cbdMD, Inc. filed an amendment (8-K/A) on August 19, 2024, to its report originally dated August 15, 2024. The amendment pertains to "Other Events" and does not provide specific details on new transactions or financial figures within the provided text.
Why It Matters
This filing indicates a procedural update or correction to a previous report, suggesting ongoing regulatory compliance or adjustments to previously disclosed information by cbdMD, Inc.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material risks or significant financial changes.
Key Players & Entities
- cbdMD, Inc. (company) — Registrant
- August 15, 2024 (date) — Original report date
- August 19, 2024 (date) — Filing date of amendment
- North Carolina (location) — State of incorporation
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previously filed Current Report on Form 8-K, dated August 15, 2024, pertaining to 'Other Events'.
When was the original report filed?
The original report was dated August 15, 2024.
When was this amendment filed?
This amendment was filed as of August 19, 2024.
What is the company's state of incorporation?
The company, cbdMD, Inc., is incorporated in North Carolina.
Does this amendment provide new financial details?
The provided text for the 8-K/A filing does not specify new financial details; it indicates an amendment to a report concerning 'Other Events'.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-19 17:23:41
Key Financial Figures
- $230,000 — riginal 8-K erroneously stated that the $230,000 non-cash amount relating to the termina
- $255,000 — t. On August 15, 2024 made a payment of $255,000 (the "Payment") to satisfy all past due
- $550,000 — ny anticipates realizing an approximate $550,000 gain on the settlement of accrued past
Filing Documents
- ycbd20240819_8ka.htm (8-K/A) — 25KB
- ycbd20240819_8kaimg001.jpg (GRAPHIC) — 3KB
- 0001437749-24-027247.txt ( ) — 182KB
- ycbd-20240815.xsd (EX-101.SCH) — 4KB
- ycbd-20240815_def.xml (EX-101.DEF) — 13KB
- ycbd-20240815_lab.xml (EX-101.LAB) — 18KB
- ycbd-20240815_pre.xml (EX-101.PRE) — 13KB
- ycbd20240819_8ka_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. As previously disclosed by cbdMD, Inc. (the "Company"), in March 2024 the Company and its former executive offices landlord ("Landlord") entered into a License Agreement and a Lease Forbearance Agreement (the "Forbearance Agreement") to terminate the lease of the Company's former executive offices (the "Former Facilities Lease"). The Company has satisfied all payment requirements under the Forbearance Agreement and License Agreement. On August 15, 2024 made a payment of $255,000 (the "Payment") to satisfy all past due payments and amounts under the Former Facilities Lease. The Company and Landlord entered into a mutual release and settlement agreement and the Company has no obligations (payments or otherwise) owed to Landlord under any of the agreements described in this current report on Form 8-K. As a result of the Payment, the Company anticipates realizing an approximate $550,000 gain on the settlement of accrued past due rent, interest and penalties. This gain is in addition to the approximate $230,000 non-cash gain that resulted from the elimination of the right of use asset and the right of use liability under the termination of the original lease.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. cbdMD, Inc. Date: August 19, 2024 By: /s/ T. Ronan Kennedy T. Ronan Kennedy, Chief Executive Officer and Chief Financial Officer